- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06355778
Adversity, Brain and Opioid Use Study
April 4, 2024 updated by: Elizabeth Duval, University of Michigan
A Mechanistic Investigation of Risk Factors for Opioid Use Disorder: Examining Hippocampal-based Context-dependent Learning and Memory Associated With Adverse Childhood Experiences
The way people process and remember information may be related to adverse childhood experiences and Opioid Use Disorder symptoms.
The purpose of this project is to examine brain function and performance during learning and memory tasks in adults.
The study will compare measures of learning and memory across three groups of participants: those with an Opioid Use Disorder (OUD) that take buprenorphine for opioid replacement therapy, adults without an Opioid Use Disorder taking buprenorphine, and healthy adults that do not have an Opioid Use Disorder and are not taking buprenorphine.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
315
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mariya Churina
- Phone Number: 734-232-0190
- Email: AdversityBrainOUD@med.umich.edu
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
Contact:
- Mariya Churina
- Email: AdversityBrainOUD@med.umich.edu
-
Principal Investigator:
- Elizabeth Duval, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria for all groups:
- Right handed
- Able to give informed consent
- Normal/corrected-to-normal vision and hearing
Inclusion Criteria for Opioid Use Disorder (OUD) group:
- Diagnosis of OUD
- Be actively receiving buprenorphine (BUP) for opioid agonist therapy
- Be free from illicit substance use for at least 2 weeks
- The study will allow stable dose (> 3 months) of commonly prescribed psychiatric medications and some sleep aids (per protocol)
Inclusion Criteria for the BUP control group:
- Taking BUP for chronic pain
- Never had a Substance Use Disorder (including OUD)
- The study will allow stable dose (> 3 months) of commonly prescribed psychiatric medications and some sleep aids (per protocol)
Inclusion Criteria for Healthy participant group:
- Not taking BUP
- Free of any psychiatric or major medical conditions
Exclusion Criteria for all groups:
- Significant medical or neurologic conditions (e.g., stroke, seizures, multiple sclerosis)
- Actively suicidal
- Contraindication for MRI
- Life history of schizophrenia, bipolar disorder, learning disability, attention deficit disorder, or pervasive developmental disorder
- Illicit substance use (past 2 weeks)
- Prescription medications that could interfere with measures of interest (per protocol)
- Unable to provide informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Opioid use disorder (OUD) group
This group takes buprenorphine and has OUD.
|
Enrolled participants will have one MRI during the study on day 2 after having Day 1 visit.
During the MRI the participants will complete various tasks.
Eligible participants will complete computer tasks (cognitive tasks, spatial navigation tasks, context dependent fear learning, etc.) at visit 1 and then during the MRI.
|
Other: Buprenorphine (BUP) control group:
This group takes BUP and does not have OUD.
|
Enrolled participants will have one MRI during the study on day 2 after having Day 1 visit.
During the MRI the participants will complete various tasks.
Eligible participants will complete computer tasks (cognitive tasks, spatial navigation tasks, context dependent fear learning, etc.) at visit 1 and then during the MRI.
|
Other: Healthy Controls group
This group does not take BUP and does not have OUD.
|
Enrolled participants will have one MRI during the study on day 2 after having Day 1 visit.
During the MRI the participants will complete various tasks.
Eligible participants will complete computer tasks (cognitive tasks, spatial navigation tasks, context dependent fear learning, etc.) at visit 1 and then during the MRI.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Differences in Blood Oxygen Level Dependent (BOLD) signal in the hippocampus
Time Frame: Day 2 (MRI task visit)
|
BOLD signal during functional magnetic resonance imaging (fMRI) will be used as a measure of hippocampus activation when remembering common objects and scenes.
The study team will examine differences between participants with Opioid Use Disorder (OUD) and those without OUD.
|
Day 2 (MRI task visit)
|
Differences in Hippocampal (Hpc) volume
Time Frame: Day 2 (MRI task visit)
|
T-1 weighted structural images for each participant will be used to compute the volume of the hippocampus in people with OUD compared to those without OUD.
|
Day 2 (MRI task visit)
|
Differences in hippocampal circuit connectivity
Time Frame: Day 2 (MRI task visit)
|
Functional connectivity, measured with BOLD signal will be used to examine functional connectivity between the hippocampus, amygdala, and prefrontal cortex.
The study team will examine differences in connectivity between participants with OUD and those without OUD.
|
Day 2 (MRI task visit)
|
Differences in performance
Time Frame: Day 1 (computer tasks visit)
|
Number of correct responses will be used to assess memory for common objects and scenes.
Differences in memory will be examined in between participants with OUD and those without OUD.
|
Day 1 (computer tasks visit)
|
Differences in performance
Time Frame: Day 2 (MRI task visit)
|
Number of correct responses will be used to assess memory for common objects and scenes.
Differences in memory will be examined in between participants with OUD and those without OUD.
|
Day 2 (MRI task visit)
|
Differences in threat reactivity measured via skin conductance response (SCR)
Time Frame: Day 1 (computer tasks visit)
|
Electrodermal activity collected with a bioamplifier will be used to quantify physiological reactivity to threat.
Event related SCR will be measured as a baseline corrected response (peak minus baseline) to cues that predict threat compared to cues that do not predict threat.
Differences in SCR between participants with OUD and participants without OUD will be examined.
|
Day 1 (computer tasks visit)
|
Differences in threat reactivity measured via skin conductance response (SCR)
Time Frame: Day 2 (MRI task visit)
|
Electrodermal activity collected with a bioamplifier will be used to quantify physiological reactivity to threat.
Event related SCR will be measured as a baseline corrected response (peak minus baseline) to cues that predicted threat on the previous day compared to cues that did not predict threat.
Differences in SCR between participants with OUD and participants without OUD will be examined.
|
Day 2 (MRI task visit)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Elizabeth Duval, University of Michigan
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
April 1, 2024
Primary Completion (Estimated)
April 1, 2028
Study Completion (Estimated)
April 1, 2028
Study Registration Dates
First Submitted
April 4, 2024
First Submitted That Met QC Criteria
April 4, 2024
First Posted (Actual)
April 9, 2024
Study Record Updates
Last Update Posted (Actual)
April 9, 2024
Last Update Submitted That Met QC Criteria
April 4, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HUM00234185
- 1R01DA056415 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
It is NIH policy that the results and accomplishments of the activities that it funds should be made available to the public.
The principal investigator (PI) will ensure all mechanisms used to share data will include proper plans and safeguards for the protection of privacy, confidentiality, and security for data dissemination and reuse (e.g., all data will be thoroughly de-identified and will not be traceable to a specific study participant).
Plans for archiving and long-term preservation of the data will be implemented, as appropriate.
IPD Sharing Time Frame
When the study is completed, access to study data will be provided by the PI as requested.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Magnetic Resonance Imaging (MRI)
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingProstate CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBrain NeoplasmUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingProstate Adenocarcinoma | Prostate CarcinomaUnited States
-
University of MichiganPhilips Healthcare; General ElectricCompleted
-
American College of RadiologyPennsylvania Department of HealthCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Recruiting
-
University of California, San FranciscoTerminatedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
University of CincinnatiActive, not recruitingProstate CancerUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Healthy SubjectUnited States
-
Ohio State University Comprehensive Cancer CenterWithdrawn